- Home
- NXTC vs IOBT Comparison
NXTC vs IOBT Comparison
Compare NXTC & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXTC | IOBT |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 57.2M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NXTC | IOBT |
|---|---|---|
| Price | $10.85 | $0.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $23.00 | $2.25 |
| AVG Volume (30 Days) | 28.6K | ★ 27.2M |
| Earning Date | 03-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.69 | $0.21 |
| 52 Week High | $15.74 | $2.79 |
Technical Indicators
Market Signals| Indicator | NXTC | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 36.17 |
| Support Level | $10.42 | $0.30 |
| Resistance Level | $11.49 | $0.34 |
| Average True Range (ATR) | 1.18 | 0.08 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 15.66 | 21.42 |
Price Performance
Historical ComparisonAbout NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.